FI119356B - Orala kompositioner vilka innehåller ondansetron - Google Patents
Orala kompositioner vilka innehåller ondansetron Download PDFInfo
- Publication number
- FI119356B FI119356B FI972168A FI972168A FI119356B FI 119356 B FI119356 B FI 119356B FI 972168 A FI972168 A FI 972168A FI 972168 A FI972168 A FI 972168A FI 119356 B FI119356 B FI 119356B
- Authority
- FI
- Finland
- Prior art keywords
- ondansetron
- composition according
- sorbitol
- composition
- range
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Dental Preparations (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (12)
1. För oral administration avsedd vätskekomposi-tion, som innehäller ondansetron eller dess farmaceutiskt 5 godtagbara derivat, sötningsmedel och ett eller flera farmaceutiskt godtagbara fyllmedel, kännetecknad av att sötningsmedlet omfattar sorbitol och att kompositionens pH är inom det sura pH-omrädet 2,0 - 5,0.
2. Komposition enligt patentkrav 1, känneteck-10 nad av att den innehäller ondansetron i form av sin hyd- roklorid.
3. Komposition enligt patentkrav 1, kännetecknad av att den innehäller ondansetron i form av sin hyd-rokloridhydrat.
4. Komposition enligt nägot av patentkraven 1-3, kännetecknad av att ondansetron är i form av sin hydrokloridhydrat, och att sötningsmedlet är sorbitol.
5. Komposition enligt nägot av patentkraven 1-4, kännetecknad av att koncentrationen av ondansetron i 2 0 kompositionen, uttryckt som fri bas, är i omrädet av 0,005 - 1 % vikt/volym.
• » · *·’·’ 6. Komposition enligt nägot av patentkraven 1-5, kännetecknad av att kompositionens totalsorbitolhalt, '·*" uttryckt som fast sorbitol, är i omrädet av 20 - 85 % :\i 25 vikt/volym.
7. Komposition enligt nägot av patentkraven 1-6, kännetecknad av att pH är inom det sura pH-omrädet • * · ^ 2,5 - 4,5.
8. Komposition enligt nägot av patentkraven 1-7, • · · *.* 30 kännetecknad av att koncentrationen av ondansetron i • * **" kompositionen, uttryckt som fri bas, är i omrädet av 0,02 - 0,2 % vikt/volym; kompositionens totalsorbitolhalt, :1: uttryckt som fast sorbitol, är i omrädet av 30 - 50 % • * * ./ vikt/volym; och att pH är inom det sura pH-omrädet 3,0 - 4,0. • · · ··« • f • · 9 · · 119356
9. Komposition enligt nägot av patentkraven 1-8, kännetecknad av att dess viskositet Sr i omrädet av 1 - 100 CP.
10. Komposition enligt nägot av patentkraven 1-9, 5 kännetecknad av att den Sr väsentligen fri frSn fruktos eller sackarid innehSllande fruktos.
11. Användning av ondansetron eller dess farmaceu-tiskt godtagbara derivat, sötningsmedel och ett eller fle-ra farmaceutiskt godtagbara fyllmedel för framställning av 10 en vätskekompositiön enligt nägot av patentkraven 1-10 för behandling av ett tillständ, som förmedlas genom verk-samheten av 5-HT vid 5-HT3-receptorer.
12. Användning enligt patentkrav 11, kännetecknad av att man behandlar uppkastning. • · • * · • · · • · • · * Λ · · *·· f * · • * · · • ·· • · ·· * · ·· *·· * · · • · · • ♦ t · I • I » • · ··· • · * · • · ® • · • · * • · • · • · · • · • · • · * » • · * · • · 1 • · • ·
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9423588A GB9423588D0 (en) | 1994-11-22 | 1994-11-22 | Compositions |
| GB9423588 | 1994-11-22 | ||
| PCT/IB1995/001152 WO1996015786A2 (en) | 1994-11-22 | 1995-11-20 | Oral compositions containing ondansetron |
| IB9501152 | 1995-11-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI972168A FI972168A (sv) | 1997-05-21 |
| FI972168A0 FI972168A0 (sv) | 1997-05-21 |
| FI119356B true FI119356B (sv) | 2008-10-31 |
Family
ID=10764811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI972168A FI119356B (sv) | 1994-11-22 | 1997-05-21 | Orala kompositioner vilka innehåller ondansetron |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5854270A (sv) |
| EP (1) | EP0792149B1 (sv) |
| JP (1) | JP2965704B2 (sv) |
| KR (1) | KR100292124B1 (sv) |
| CN (1) | CN1108153C (sv) |
| AT (1) | ATE196084T1 (sv) |
| AU (1) | AU703932B2 (sv) |
| BE (1) | BE1009458A5 (sv) |
| BR (1) | BR9509807A (sv) |
| CA (1) | CA2205546C (sv) |
| CY (1) | CY2171B1 (sv) |
| CZ (1) | CZ285187B6 (sv) |
| DE (1) | DE69518767T2 (sv) |
| DK (1) | DK0792149T3 (sv) |
| ES (1) | ES2151083T3 (sv) |
| FI (1) | FI119356B (sv) |
| FR (1) | FR2727015B1 (sv) |
| GB (2) | GB9423588D0 (sv) |
| GR (1) | GR3034684T3 (sv) |
| HK (1) | HK1009590A1 (sv) |
| HU (1) | HU226947B1 (sv) |
| IE (1) | IE950884A1 (sv) |
| IL (1) | IL116083A (sv) |
| IT (1) | IT1282353B1 (sv) |
| NO (1) | NO306892B1 (sv) |
| NZ (1) | NZ297879A (sv) |
| PL (1) | PL181522B1 (sv) |
| PT (1) | PT792149E (sv) |
| RU (1) | RU2145853C1 (sv) |
| SI (1) | SI0792149T1 (sv) |
| TW (1) | TW413634B (sv) |
| WO (1) | WO1996015786A2 (sv) |
| ZA (1) | ZA959820B (sv) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2162561B1 (es) * | 1999-06-28 | 2002-07-16 | Boehringer Ingelheim Espana | Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable. |
| US6473876B1 (en) | 1999-06-29 | 2002-10-29 | Sony Corporation | Method and apparatus for encoding of bitstreams using rotation |
| EP1206264A2 (en) * | 1999-08-25 | 2002-05-22 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
| YU32003A (sh) * | 2000-10-30 | 2006-05-25 | Teva Pharmaceutical Industries Ltd. | Novi kristalni i solvatni oblici ondansteron hlorovodonika i postupci za njihovo pripremanje |
| US20020115707A1 (en) * | 2001-01-11 | 2002-08-22 | Rami Lidor-Hadas | Process for preparing pure ondansetron hydrochloride dihydrate |
| MXPA04009968A (es) * | 2002-04-09 | 2004-12-13 | Flamel Tech Sa | Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s). |
| PL373191A1 (en) * | 2002-04-29 | 2005-08-22 | Teva Gyogyszergyar Reszvenytarsasag | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one |
| US20050131045A1 (en) * | 2002-04-30 | 2005-06-16 | Judith Aronhime | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
| CA2483532A1 (en) * | 2002-04-30 | 2003-11-13 | Biogal Gyogyszergyar Rt. | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them |
| DE10393729T5 (de) * | 2002-11-15 | 2005-10-13 | Helsinn Healthcare S.A. | Verfahren zur Behandlung von Emesis |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| TWI355936B (en) * | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| US20060167072A1 (en) * | 2004-01-30 | 2006-07-27 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| JP2006028028A (ja) * | 2004-07-12 | 2006-02-02 | Teikoku Medix Kk | 経口医薬組成物 |
| CN100423779C (zh) * | 2006-09-27 | 2008-10-08 | 中国药科大学 | 一种以5－羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途 |
| JP2010522135A (ja) | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
| US20110201597A1 (en) | 2008-03-27 | 2011-08-18 | Chase Thomas N | Method and composition for treating alzheimer-type dementia |
| CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| MX345236B (es) * | 2009-09-18 | 2017-01-23 | Chase Pharmaceuticals Corp | Metodo y composicion para tratar la demencia de tipo alzheimer. |
| US20110288115A1 (en) * | 2010-05-24 | 2011-11-24 | Avmedis Llc | Treatment of vagally-mediated spectrum disorders |
| US20120302616A1 (en) * | 2010-12-03 | 2012-11-29 | Nikhilesh Singh | Method of treatment of obsessive compulsive disorder with ondansetron |
| KR101058749B1 (ko) * | 2010-12-29 | 2011-08-24 | 에스씨바이오팜 주식회사 | 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물 |
| IN2015DN01706A (sv) | 2012-09-05 | 2015-05-22 | Chase Pharmaceuticals Corp | |
| US10172833B2 (en) | 2015-08-11 | 2019-01-08 | Insys Development Company, Inc. | Sublingual ondansetron spray |
| KR101635820B1 (ko) * | 2015-10-30 | 2016-07-04 | 재단법인 통합의료진흥원 | 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물 |
| JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| KR101721094B1 (ko) * | 2016-09-09 | 2017-03-29 | 재단법인 통합의료진흥원 | 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물 |
| KR102675602B1 (ko) * | 2023-09-01 | 2024-06-14 | (주)옥천당 | 항암제 투여시 유발되는 소화관 장애의 효과적 제어가 가능한 신규 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2561244B1 (fr) * | 1984-01-25 | 1988-03-04 | Glaxo Group Ltd | Composes heterocycliques du type tetrahydrocarbazolone, procede pour leur preparation et composition pharmaceutique les comprenant |
| EP0450757A3 (en) * | 1990-02-22 | 1993-09-15 | Glaxo Group Limited | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood |
| ITMI922854A1 (it) * | 1992-12-15 | 1994-06-15 | Boehringer Ingelheim Italia | Uso degli antagonisti dei recettori 5-ht3 |
-
1994
- 1994-11-22 GB GB9423588A patent/GB9423588D0/en active Pending
-
1995
- 1995-11-20 PL PL95320288A patent/PL181522B1/pl unknown
- 1995-11-20 BR BR9509807A patent/BR9509807A/pt not_active Application Discontinuation
- 1995-11-20 CN CN95197225A patent/CN1108153C/zh not_active Expired - Lifetime
- 1995-11-20 CZ CZ971548A patent/CZ285187B6/cs not_active IP Right Cessation
- 1995-11-20 GB GB9523666A patent/GB2295317B/en not_active Expired - Lifetime
- 1995-11-20 DK DK95941825T patent/DK0792149T3/da active
- 1995-11-20 AU AU43135/96A patent/AU703932B2/en not_active Expired
- 1995-11-20 ES ES95941825T patent/ES2151083T3/es not_active Expired - Lifetime
- 1995-11-20 ZA ZA959820A patent/ZA959820B/xx unknown
- 1995-11-20 AT AT95941825T patent/ATE196084T1/de active
- 1995-11-20 WO PCT/IB1995/001152 patent/WO1996015786A2/en active IP Right Grant
- 1995-11-20 CA CA002205546A patent/CA2205546C/en not_active Expired - Lifetime
- 1995-11-20 HU HU9800736A patent/HU226947B1/hu unknown
- 1995-11-20 PT PT95941825T patent/PT792149E/pt unknown
- 1995-11-20 SI SI9530444T patent/SI0792149T1/xx unknown
- 1995-11-20 DE DE69518767T patent/DE69518767T2/de not_active Expired - Lifetime
- 1995-11-20 RU RU97110066A patent/RU2145853C1/ru active
- 1995-11-20 JP JP8516719A patent/JP2965704B2/ja not_active Expired - Lifetime
- 1995-11-20 KR KR1019970703400A patent/KR100292124B1/ko not_active IP Right Cessation
- 1995-11-20 US US08/817,831 patent/US5854270A/en not_active Expired - Lifetime
- 1995-11-20 EP EP95941825A patent/EP0792149B1/en not_active Expired - Lifetime
- 1995-11-20 NZ NZ297879A patent/NZ297879A/xx not_active IP Right Cessation
- 1995-11-20 IT IT95RM000763A patent/IT1282353B1/it active IP Right Grant
- 1995-11-20 FR FR9513722A patent/FR2727015B1/fr not_active Expired - Lifetime
- 1995-11-20 IE IE950884A patent/IE950884A1/en not_active IP Right Cessation
- 1995-11-21 BE BE9500956A patent/BE1009458A5/fr active
- 1995-11-21 IL IL11608395A patent/IL116083A/xx not_active IP Right Cessation
- 1995-12-13 TW TW084113264A patent/TW413634B/zh not_active IP Right Cessation
-
1997
- 1997-05-21 FI FI972168A patent/FI119356B/sv not_active IP Right Cessation
- 1997-05-21 NO NO972324A patent/NO306892B1/no not_active IP Right Cessation
-
1998
- 1998-09-04 HK HK98110451A patent/HK1009590A1/xx not_active IP Right Cessation
-
2000
- 2000-05-23 CY CY0000018A patent/CY2171B1/xx unknown
- 2000-10-26 GR GR20000402371T patent/GR3034684T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI119356B (sv) | Orala kompositioner vilka innehåller ondansetron | |
| FI119355B (sv) | Frystorkade ondansetronkompositioner | |
| EP2273975B1 (en) | Pharmaceutical solutions, process of preparation and therapeutic uses | |
| US20080160087A1 (en) | Gel preparation for oral administration | |
| US11564909B2 (en) | Methods and compositions for oral pilocarpine liquid | |
| KR101058749B1 (ko) | 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물 | |
| MXPA97003734A (en) | Oral compositions containing ondanset | |
| CA2205600C (en) | Freeze-dried ondansetron compositions | |
| RU2165255C1 (ru) | Антигистаминная композиция | |
| CA2619367A1 (en) | Gel preparation for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 119356 Country of ref document: FI |
|
| PC | Transfer of assignment of patent |
Owner name: GLAXOSMITHKLINE INC. |
|
| MA | Patent expired |